Telix Pharmaceuticals and Cardinal Health Enter into Distribution Agreement for Prostate Cancer Imaging
October 02 2018 - 8:00PM
Telix Pharmaceuticals (US) Inc. (“Telix USA”), a subsidiary of
Telix Pharmaceuticals Limited (ASX:TLX), a clinical-stage
biopharmaceutical company focused on the development of diagnostic
and therapeutic products based on targeted radiopharmaceuticals or
“molecularly-targeted radiation” (MTR) today announced that it has
entered into a distribution agreement with Cardinal Health
(NYSE:CAH).
The agreement covers pharmacy preparation and
distribution of the 68Ga-HBED-CC-PSMA-11 imaging cold kit
(68Ga-PSMA Kit), developed by ANMI SA and commercialized for the US
market by Telix USA. Under the terms of the agreement, Cardinal
Health can both distribute the 69Ga-PSMA Kit and prepare unit doses
of 68Ga-PSMA delivered as an investigational product for use in
qualified investigator-sponsored clinical trials, including
Telix-sponsored clinical trials.
Telix USA President Bernard Lambert stated, “We
are pleased to be working with Cardinal Health for the preparation
and delivery of 68Ga-PSMA across the Cardinal Health network, the
largest nuclear pharmacy distribution network in the United States.
Following the successful filing of a drug master file for the
68Ga-PSMA Kit with the FDA, we believe this agreement with Cardinal
Health puts us in a position to play a key role in the clinical
development and adoption of PSMA prostate cancer imaging in the
US.”
About the US Prostate Cancer Imaging Market
Other than skin cancer, prostate cancer is the
most common male cancer in the United States, with approximately
160,000 new cases annually and three million men living with
prostate cancer.1 There remains a major unmet need to better
diagnose and stage men with prostate cancer, from initial diagnosis
all the way to therapeutic monitoring in patients with late-stage
metastatic disease. The prostate imaging market in the US is
estimated to be a $500 million market opportunity, likely to be
dominated by the use of Positron Emission Tomography (PET) and
imaging agents targeting prostate-specific membrane antigen (PSMA)
in particular.2
About Telix Pharmaceuticals
Limited
Telix Pharmaceuticals Limited (“Telix”) is a
global biopharmaceutical company focused on the development of
diagnostic and therapeutic products based on targeted
radiopharmaceuticals or “molecularly-targeted radiation” (MTR). The
company is headquartered in Melbourne with international operations
in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is
developing a portfolio of clinical-stage oncology products that
address significant unmet medical need in renal, prostate and brain
(glioblastoma) cancer. Telix is listed on the Australian Securities
Exchange (ASX:TLX). For more information visit:
www.telixpharma.com.
About Cardinal Health Nuclear Pharmacy
Solutions
The Cardinal Health Nuclear Pharmacy Services
organization manufactures, compounds, dispenses and delivers over
10 million time-critical, patient-specific doses annually. It is a
leading nuclear medicine service provider with 40 years of
experience, 133 nuclear pharmacies, and 34 strategically located
PET manufacturing facilities across the United States. For more
information visit:
www.cardinalhealth.com/en/product-solutions/pharmaceutical-products/nuclear-medicine
Important Information
This announcement does not constitute an offer
to sell, or a solicitation of an offer to buy, securities in the
United States, or in any other jurisdiction in which such an offer
would be illegal. The securities referred to herein have not been
and will not be registered under the United States Securities Act
of 1933 (the “US Securities Act”), or under the securities laws of
any state or other jurisdiction of the United States and may not be
offered or sold within the United States, unless the securities
have been registered under the US Securities Act or an exemption
from the registration requirements of the US Securities Act is
available. None of the products described in this release have
obtained a marketing authorization from the US Food and Drug
Administration.
______________________________
1 American Cancer Society :
https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html 2
Jadvar et al. J Nucl Med February 1, 2018 vol. 59 no. 2 228-229
Telix Corporate Contact
Dr. Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com
Telix Investor Relations (Australia)
Kyahn Williamson
WE Buchan
Tel: +61 (3) 9866 4722
Email: kwilliamson@buchanwe.com.au
Telix Investor Relations (US)
Lisa Wilson
In-Site Communications
Tel: +1 212 452 2793
Email: lwilson@insitecony.com
Cardinal Health (NYSE:CAH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cardinal Health (NYSE:CAH)
Historical Stock Chart
From Sep 2023 to Sep 2024